amuvatinib
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2007 (NCT00504205)
Timeline
Indications
Mechanism of action
PDGFRA inhibitor
Inhibits mutant forms of KIT, FLT3 and PDGFRA (http://www.google.com/patents/US20080226747).
- Stem cell growth factor receptorINHIBITOR
KIT inhibitor
Inhibits mutant forms of KIT, FLT3 and PDGFRA (http://www.google.com/patents/US20080226747).
FLT3 inhibitor
Inhibits mutant forms of KIT, FLT3 and PDGFRA (http://www.google.com/patents/US20080226747).
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Inhibits mutant forms of KIT, FLT3 and PDGFRA (http://www.google.com/patents/US20080226747).
Chemistry & pharmacology
Loading structure…
SMILES
S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1- Mol. weight
- 447.52 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2103851 ↗
Also known as
- amuvatinib
- amuvatinib
- amuvatinib
- amuvatinib
- amuvatinib
- hpk56
- hpk56
- hpk-56
- hpk-56
- mp470
- mp470
- mp470
- mp-470
- mp-470
- mp-470
- mp-470
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01357395 | Phase 2 | May 1, 2011 | Astex Pharmaceuticals, Inc. |
| NCT00881166 | Phase 1 | Nov 1, 2007 | Astex Pharmaceuticals, Inc., Premiere Oncology, The START Center for Cancer Care |
| NCT00504205 | N/A | May 1, 2007 | Astex Pharmaceuticals, Inc. |
| NCT00894894 | Phase 1 | May 1, 2007 | Astex Pharmaceuticals, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astex Pharmaceuticals, Inc. | For profit | 4 | 4 | 3 | 2007 |
| Premiere Oncology | For profit | 1 | 0 | 1 | 2007 |
| The START Center for Cancer Care | Academic/Hospital | 1 | 0 | 1 | 2007 |
3 organizations
Page 1 / 1